Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

July 5, 2023

Study Completion Date

July 5, 2023

Conditions
Non Alcoholic SteatohepatitisFibrosis
Interventions
DRUG

Idebenone

Idebenone, initially 200mg by mouth (P.O.) once a day for 2 weeks, then 200 mg twice a day for 2 weeks, then 200 mg three times per day for the remainder of the study will be used.

DRUG

Placebo

Placebo to match Idebenone once a day for 2 weeks, then twice a day for 2 weeks, then three times per day for the remainder of the study will be used.

Trial Locations (2)

94063

Digestive Health Center, Stanford University, Redwood City

94305

Stanford University, Stanford

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Stanford University

OTHER

NCT04669158 - Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis | Biotech Hunter | Biotech Hunter